Dicks Sporting Goods Inc vs Heron Therapeutics Inc — how do they compare? Dicks Sporting Goods Inc trades at $206.29 (market cap $19.16B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Dicks Sporting Goods Inc is far larger — about 302.2× Heron Therapeutics Inc's market cap, and Dicks Sporting Goods Inc pays a 2.34% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DKS | HRTX | |
|---|---|---|
Market Cap | $19.16B | $63.41M |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $1.49 |
52-Week Low | $187.78 | $0.32 |
Enterprise Value | $25.95B | $161.31M |
Dividend Yield | 2.34% | — |
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $208.84, up 5.15% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals with support at $201 and resistance at $213. Fundamentally, the company maintains solid profitability with 20.9% ROE and 4.71% net margin, though cash flow trends show modest net outflows. Recent news highlights analyst upgrades and the upcoming Q2 earnings call on August 25th.
The investment outlook remains positive with 59% analyst buy ratings and a $263.22 consensus target representing 26% upside. Key risks include potential fiduciary duty investigations and competitive pressures in sporting goods retail. The company's consistent earnings beats and expanding women's sports investments provide catalysts, though investors should monitor cash flow sustainability and market volatility.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →